Download Product Insert (PDF)

PRODUCT INFORMATION Fosamprenavir (calcium salt) Item No. 21609

CAS Registry No.: 226700-81-8 Formal Name: N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-1-(phenylmethyl)- 2-(phosphonooxy)propyl]-carbamic acid, (3S)-tetrahydro-3-furanyl ester, OO

monocalcium salt O Synonym: GW 433908G O S N N MF: C H N O PS • Ca O 25 34 3 9 H FW: 623.7 O -O P Purity: ≥98% NH2 O- • Ca2+ UV/Vis.: λmax: 268 nm O Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fosamprenavir (calcium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the fosamprenavir (calcium salt) in the solvent of choice. Fosamprenavir (calcium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of fosamprenavir (calcium salt) in ethanol is approximately 2 mg/ml and approximately 30 mg/ml in DMSO and DMF. Fosamprenavir (calcium salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, fosamprenavir (calcium salt) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Fosamprenavir (calcium salt) has a solubility of approximately 0.11 mg/ml in a 1:8 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Fosamprenavir (calcium salt) is an orally bioavailable prodrug of the HIV-1 protease inhibitor amprenavir (Item No. 15369).1 Fosamprenavir has improved solubility compared with amprenavir, and its pharmacokinetics, either during fasting or with a low- or high-fat meal, suggest that it could be effective using fewer tablets and a less complex dosing schedule than other HIV treatments.2 Formulations containing fosamprenavir are used for adult and pediatric patients with HIV infection, especially as an initial antiretroviral therapy.3

References

1. Chapman, T.M., Plosker, G.L., and Perry, C.M. Fosamprenavir: A review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs 64(18), 2101-2124 (2004). 2. Falcoz, C., Jenkins, J.M., Bye, C., et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J. Clin. Pharmacol. 42, 887-898 (2002). 3. Ross, L.L., Cotton, M.F., Cassim, H., et al. Treatment-emergent mutations and resistance in HIV-infected children treated with fosamprenavir-containing antiretroviral regimens. Open AIDS J. 9, 38-44 (2015).

WARNING CAYMAN CHEMICAL THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE. 1180 EAST ELLSWORTH RD SAFETY DATA ANN ARBOR, MI 48108 · USA This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution. PHONE: [800] 364-9897

WARRANTY AND LIMITATION OF REMEDY [734] 971-3335 Buyer agrees to purchase the material subject to Cayman’s Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website. FAX: [734] 971-3640 [email protected] Copyright Cayman Chemical Company, 04/21/2017 WWW.CAYMANCHEM.COM